AngioDynamics(NASDAQ) ANGO

AngioDynamics makes tools to treat cancer and heart disease. These medical devices help surgeons clear clots or remove tumors. They help patients recover faster using less invasive methods.

Modern Tools for Complex Care

• Med Tech: Specialized systems including Auryon and NanoKnife for treating vascular disease and cancer; generated $150.0 million in net sales during fiscal year 2026.
• Thrombectomy: Mechanical devices designed to remove blood clots without major surgery; operates within the Med Tech segment which grew 18.4% in fiscal year 2026.
• Med Device: Core products such as catheters and guidewires used in minimally invasive diagnostic procedures; generated $170.2 million in net sales during fiscal year 2026.
• Vascular Access: Implantable ports that allow long-term medication delivery for patients requiring frequent infusions; marketed under brand names like BioFlo and SmartPort.

Strategic Moves and Market Shifts

• Completed the sale of dialysis and BioSentry businesses to Merit Medical Systems in June 2023.
• Sold the peripherally inserted central catheter and midline catheter businesses to Spectrum Vascular in February 2024.
• Announced a restructuring plan in January 2024 to outsource manufacturing and generate $15.0 million in annual cost savings starting in fiscal year 2027.
• Received expanded Food and Drug Administration clearance for the NanoKnife system for the ablation of prostate tissue in December 2024.
• Discontinued the radiofrequency ablation and Syntrax product lines as of Feb. 29, 2024.

Cutting Edge Clinical Design

The company focuses on irreversible electroporation technology that uses electrical pulses to kill diseased cells while preserving surrounding tissue structures. It maintains a direct sales force in the United States to target specialists in interventional radiology, vascular surgery, and oncology.

Results for Fiscal Year 2026

• Net sales rose 9.5% to $320.2 million during fiscal year 2026.
• Med Tech segment sales grew 18.4% year over year in fiscal year 2026.
• Gross margin reached 54.6% in fiscal year 2026, an increase of 70 basis points.
• Net loss increased by $2.7 million to $36.7 million during fiscal year 2026.
• Cash provided by operations was $3.1 million for the year ended May 31, 2026, an increase of $13.2 million.

Bottom Line

AngioDynamics has transitioned from a general medical supplier to a specialized technology firm focused on high-growth areas like clot management and oncology. Its shift toward outsourced manufacturing aims to improve profitability while maintaining its research-driven product portfolio.